COLODETECT

Protein Alternatives (ProAlt) is a young biotech company developing innovative products for colorectal cancer early diagnosis in blood and novel therapeutic antibodies for the treatment of colon, breast and melanoma metastatic tumors... The objective of the project is the development and commercialization of a blood-based diagnostic test for the early detection of CRC. The outlined test will detect several antibodies generated by the immune system from patients against the tumor. These auto-antibodies appear at detectable levels in patient's blood before symptoms and allow early diagnosis. CRC is the second most frequent and most deadly neoplasia worldwide. Survival rate is highly related to cancer stage at diagnosis. Only 30-40% of colon cancer cases are diagnosed in early stages. More than 9 in 10 colon cancer patients will survive the disease for more than 5 years if diagnosed at the earliest stage. The simplicity of COLODETECT will allow the screening of large population at risk...

Primary location: Boston United States